3/23/2010

Molecular Insight Pharmaceuticals started a first-stage study of Solazed, its experimental radiotherapeutic drug for malignant-metastatic melanoma. The National Cancer Institute is funding the clinical trial through a grant worth as much as $1.5 million.

Related Summaries